Communiqués Genetic Analysis

Actions

GEAN

NO0010692130

Cours en clôture NORDIC GROWTH MARKET Autres places de cotation 00:00:00 25/06/2024			Varia. 5j.	Varia. 1 janv.
0,68 ^NOK	0,00%		-5,56%	-20,00%

29/05	Genetic Analysis AS publie ses resultats pour le premier trimestre clos le 31 mars 2024	CI
29/02	Genetic Analysis AS publie ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Genetic Analysis: Awarded important EU patent covering a companion diagnostic method for optimising IBS interventions	13/06	AQ
Genetic Analysis AS: CFO resigns to pursue other opportunities	06/06	AQ
Genetic Analysis AS: Mandatory notification of trade - Primary Insider	31/05	AQ
Genetic Analysis AS: Publication of Q1 report January - March 2024	29/05	AQ
Minutes from the Annual General Meeting 2024 in Genetic Analysis AS	15/05	AQ
Genetic Analysis AS: Notice of Annual General Meeting 2024	24/04	AQ
Genetic Analysis AS: Mandatory notification of trade - Primary Insider	19/04	AQ
Genetic Analysis AS: Publication of Annual Report 2023	18/04	AQ
Genetic Analysis AS: Mandatory notification of trade - Primary Insider	11/03	AQ
Year-end report January - December 2023	29/02	AQ
Genetic Analysis AS: Genetic Analysis AS announces CE-IVDR marking for its GA-map® Sample Collection Kit	26/02	AQ
Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises	10/01	AQ
Genetic Analysis announces final outcome of the subsequent offering to existing shareholders	27/12	AQ
Genetic Analysis announces preliminary outcome of the subsequent offering to existing shareholders	22/12	AQ
Genetic Analysis partners up to enter the consumer market with GA-map®	21/12	AQ
Genetic Analysis summarizes this year's product development activities and looks ahead to 2024	13/12	AQ
Today, the subscription period in Genetic Analysis subsequent offering begins	11/12	AQ
Genetic Analysis publishes information memorandum relating to the previously announced subsequent offering	08/12	AQ
Genetic Analysis announces final number of subscription rights received per existing share in the previously announced subsequent offering	08/12	AQ
Genetic Analysis announces terms of the previously announced subsequent offering to shareholders of up to appr. NOK 9 million	30/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Genetic Analysis

Actions

GEAN

NO0010692130

Communiqués

Filtres